Alzheimer's Prevention Initiative

What Alzheimer's Prevention Initiative does

The Alzheimer's Prevention Initiative (API) is a privately held, for-profit organization that has built its operating identity around exceptionally large participant registries and dedicated genetic and biomarker-testing programs targeted at Alzheimer's disease prevention. The company's core product is a screening and cohort infrastructure — large-scale registries that combine genetic and biomarker characterization of participants — which serves as the foundational asset for preclinical and prevention-stage Alzheimer's research. The organization is led by Robert Alexander, who serves as Chief Scientific Officer, indicating that scientific direction is concentrated at the executive level.

The organization's business model and revenue mechanics are not disclosed in the available data. Its operations, as described, are research-oriented and most plausibly serve pharmaceutical companies, academic research centers, and clinical trial sponsors that require pre-screened, biomarker-characterized cohorts for Alzheimer's prevention and early-intervention trials. The website (https://alzheimerspreventioninitiative.com/) currently renders only a loading/verification page, and no detailed product catalog, pricing, customer roster, or partnership history is publicly available in the data reviewed. As a result, the commercial positioning of API — including go-to-market motion, pricing models, and revenue diversification — cannot be characterized from the current evidence base and represents a significant information gap for any investment analysis.

Name

Alzheimer's Prevention Initiative

Website

https://alzheimerspreventioninitiative.com

Company type

Private

Short description

The Alzheimer's Prevention Initiative is a private for-profit organization that builds exceptionally large registries and genetic and biomarker-testing programs to support Alzheimer's disease prevention research, most likely serving pharmaceutical sponsors, academic researchers, and clinical trial operators needing pre-screened cohorts.

Ownership category

akta.pro rank

Product category

Alzheimer's Disease Prevention Research

NAICS

Voluntary Health Organizations (813212), Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Patient Registries & Chronic Disease Registry Analytics (HLACAHAH), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

Keywords

• Alzheimer's prevention research
• Genetic biomarker testing
• Clinical research registries
• Neurodegenerative disease studies
• Prevention science programs

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

Alzheimer's Prevention Initiative has developed exceptionally large registries and genetic and biomarker-testing programs. The organization operates research infrastructure focused on Alzheimer's disease prevention, supporting participant cohort development and laboratory testing for prevention-oriented studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Alzheimer's Prevention Registries Exceptionally large participant registries built for Alzheimer's prevention research, used to identify and characterize at-risk individuals for prevention studies.
• Genetic Testing Programs for Alzheimer's Prevention Genetic testing programs developed to support Alzheimer's prevention research, providing genotype-level data for cohort characterization and risk stratification.
• Biomarker Testing Programs for Alzheimer's Prevention Biomarker testing programs developed to support Alzheimer's prevention research, enabling laboratory measurement of disease-related biomarkers in research participants.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Others

• Eisai:

Emerging players

• Cerveau Technologies: Focused on tau PET imaging biomarkers for Alzheimer's and neurodegeneration; smaller, biomarker-only player in the same Alzheimer's disease-modification ecosystem as the subject company.
• 23andMe: Consumer genetics company with large genotype+phenotype datasets, including an Alzheimer's risk variant (APOE) report — overlapping genetic-testing-and-registry capability, though oriented to consumers rather than clinical prevention trials.
• Cognition Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for Alzheimer's, reliant on biomarker-stratified trial designs — comparable end-market and reliance on the same biomarker infrastructure the subject company is building.
• Araclon Biotech: Spanish biotech developing blood-based and genetic biomarkers for early Alzheimer's diagnosis — narrower biomarker focus but directly comparable early-detection/prevention positioning.

Broad incumbents

• Alzheimer's Association: Largest US voluntary health organization for Alzheimer's, funding research, registries, and biomarker programs while also advocating on policy — comparable disease-specific scope with much broader institutional reach.
• Biogen: Large biotech with leading Alzheimer's franchise (e.g., Aduhelm, Leqembi partnership with Eisai), active in biomarker-stratified treatment and prevention research — comparable end-market, far larger scale.
• Eli Lilly (Lilly Alzheimer's): Major pharma running large-scale Alzheimer's prevention trials (e.g., AHEAD) leveraging genetic/biomarker stratification — directly competing for the same prevention cohort and biomarker infrastructure space.

Direct peers

• Banner Alzheimer's Institute: Nonprofit research institute that originated and operates the Alzheimer's Prevention Initiative (API) program — same registry/prevention cohort mission as the subject company and the closest direct conceptual peer.
• Alzheimer's Drug Discovery Foundation (ADDF): Funds and advances biomarker and prevention-oriented drug discovery for Alzheimer's and related dementias; operates at the intersection of registries, biomarkers, and translational research similar to the subject company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheimer's Prevention Initiative